Clinical Classification of Immunotherapeutic Response in Patients


Immunotherapeutics, including Checkpoint inhibitors (CIs), show great promise in treating diseases including cancer, however, only a small percentage of patients respond well to these therapeutics. Because Immunotherapeutics are expensive and are associated with severe adverse side effects, screening is necessary to determine if a patient is likely to respond favorably to them. Current approaches to stratify patients based on likelihood to respond to CI treatment are ineffective and expensive.

Immunosignaturing is a unique platform that aims to detect complex patterns of antibodies produced in acute or chronic disease. The platform consists of a peptide microarray with 10,000 to over 300,000 peptides per assay and generates a vast amount of data.

Stephen Albert Johnston at the Biodesign Institute of Arizona State University has utilized the immunosignature platform as a simple and inexpensive test for stratifying patients who will respond well to immunotherapy. Using just a drop of blood, this test could screen patients to determine if they could be candidates for immunotherapy treatment.  This test could also classify a patient as having a good prognosis or a poor prognosis, based on their immunosignature. This platform provides a better correlate than current approaches for determining immunotherapy responsiveness.

Given the cost and potential side effects, this simple and inexpensive test could have a huge impact in patient selection efforts for therapies.

Potential Applications

•       Test for stratifying patients that respond to immunotherapy including checkpoint inhibitors

•       Prognostic testing based on immunosignatures

Benefits and Advantages

•       Simple and inexpensive

•       Can be quantified in multiple ways

o       Number of motifs

o       The percent of signature represented

o       Total immune reactivity

•       Only a drop of blood is needed

•       May provide a better correlate than current approaches for determining immunotherapy responsiveness

For more information about the inventor(s) and their research, please see
Dr. Johnston’s directory webpage

Case ID:
Last Updated:


Stephen Johnston

Patent Information

For More Information, Contact